@prefix this: <http://www.tkuhn.ch/bel2nanopub/RA9DxJSOnpsAOvVZ_ZEKz0KGsRpUKJNSr1WUZr8bhK4N8> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RA9DxJSOnpsAOvVZ_ZEKz0KGsRpUKJNSr1WUZr8bhK4N8#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0042789 .
  
  sub:_2 geneProductOf: hgnc:700;
    a Protein: .
  
  sub:_3 geneProductOf: hgnc:12680;
    a Protein: .
  
  sub:_4 occursIn: obo:CL_0000235, obo:UBERON_0004535, species:9606;
    rdf:object sub:_3;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "tscript(p(HGNC:ARNT)) -> p(HGNC:VEGFA)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_6;
    pav:version "20131211" .
  
  sub:_5 prov:value "Given the multiplicity of mechanisms activating the HIF system in cancer, and the many HIF target genes involved in the angiogenic process, it is tempting to propose a simple system whereby activation of HIF in cancer promotes angiogenesis and hence tumor growth. If true, such a model would strongly support the HIF system as an anticancer target.  Several studies have sought to test this model genetically in studies of experimental tumor formation by cells that are defective in particular components of the HIF pathway. The first of these used a series of mouse hepatoma cells that are functionally defective for HIF-1beta and cannot form an active HIF complex. When grown as subcutaneous tumors, the mutant cells manifest a near-total loss of the peri-necrotic enhancement of VEGF gene expression that is apparent in wild-type cells. This was associated with marked reductions in tumor angiogenesis and growth rates106. Similar reductions in growth and vascular density in tumors grown from human colon and breast carcinoma cell lines have been observed after expression of a peptide that antagonizes HIF transcription by abrogating the interaction of HIF-alpha and p300 (ref. 107).";
    prov:wasQuotedFrom pubmed:12778166 .
  
  sub:_6 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:12778166;
    prov:wasDerivedFrom beldoc:, sub:_5 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:32:02.705+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}